Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OGI Stock Forecast 2025-2026
$1.18
Current Price
$157.86M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to OGI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
OGI Price Momentum
+1.7%
1 Week Change
+13.6%
1 Month Change
-33.5%
1 Year Change
-27.3%
Year-to-Date Change
-44.3%
From 52W High of $2.11
+38.2%
From 52W Low of $0.85
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Organigram (OGI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OGI and similar high-potential opportunities.
Latest OGI Stock Price Targets & Analyst Predictions
OGI has shown a year-to-date change of -27.3% and a 1-year change of -33.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OGI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OGI Analyst Ratings
4
Buy
1
Hold
0
Sell
OGI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.18
Latest OGI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OGI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 17, 2023 | Stifel | Andrew Partheniou | Buy | Maintains | $4.00 |
| May 11, 2021 | CIBC | John Zamparo | Neutral | Upgrade | $0.00 |
| Apr 14, 2021 | CIBC | John Zamparo | Underperformer | Downgrade | $3.25 |
| Mar 10, 2021 | BMO Capital | Underperform | Downgrade | $0.00 | |
| Jan 9, 2020 | Raymond James | Market Perform | Downgrade | $0.00 | |
| Nov 12, 2019 | BMO Capital | Market Perform | Downgrade | $0.00 | |
| Oct 11, 2019 | Jefferies | Buy | Upgrade | $0.00 | |
| Feb 25, 2019 | Jefferies | Buy | Initiates | $0.00 |
Organigram Holdings Inc. (OGI) Competitors
The following stocks are similar to Organigram based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Organigram Holdings Inc. (OGI) Financial Data
Organigram Holdings Inc. has a market capitalization of $157.86M with a P/E ratio of -2.5x. The company generates $119.42M in trailing twelve-month revenue with a -31.7% profit margin.
Revenue growth is +17.2% quarter-over-quarter, while maintaining an operating margin of -15.9% and return on equity of -14.9%.
Valuation Metrics
Market Cap
$157.86M
Enterprise Value
$105.59M
P/E Ratio
-2.5x
PEG Ratio
-16.9x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+17.2%
Gross Margin
+32.3%
Operating Margin
-15.9%
Net Margin
-31.7%
EPS Growth
+17.2%
Financial Health
Cash/Price Ratio
+31.6%
Current Ratio
3.4x
Debt/Equity
2.8x
ROE
-14.9%
ROA
-11.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Organigram Holdings Inc. (OGI) Business Model
About Organigram Holdings Inc.
What They Do
Produces and sells cannabis and derived products.
Business Model
The company operates within the cannabis industry, focusing on both medical and adult-use markets. It generates revenue through the sale of a diverse range of cannabis products, including dried flower, pre-rolls, edibles, and vape oils, while leveraging advanced cultivation technologies to ensure product quality and consistency.
Additional Information
Headquartered in Moncton, New Brunswick, the company plays a significant role in the North American cannabis market and is actively involved in navigating regulatory challenges and industry developments. Organigram's commitment to research and product innovation positions it well for growth in a rapidly evolving sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,093
CEO
Ms. Beena G. Goldenberg
Country
Canada
IPO Year
2014
Website
www.organigram.caOrganigram Holdings Inc. (OGI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.82% and 0.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 01, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Organigram Global Inc. (NASDAQ: OGI), Canada's top cannabis company, has been named Exporter of the Year by Opportunities New Brunswick at the 2025 New Brunswick Export Awards, highlighting its international growth.
Why It Matters
Organigram's recognition as Exporter of the Year highlights its growth and competitiveness in the cannabis sector, potentially boosting investor confidence and attracting interest in its stock.
Source: Business Wire
Market Sentiment:
Neutral
Organigram Global's Collective Project Wins Big at the 2025 High Spirits Awards in California
4 days ago
Quick Summary
Organigram Global Inc. (NASDAQ: OGI) announced that its newly acquired brand, Collective Project, won a gold and a platinum award at the 2025 High Spirits Awards shortly after its U.S. launch.
Why It Matters
Organigram's award-winning products enhance its market position and brand reputation, potentially driving sales growth and investor confidence in the competitive cannabis sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Organigram Global Inc. (NASDAQ: OGI) will report Q2 fiscal 2025 earnings on May 12, 2025, before market open, and hold a conference call at 8:00 AM ET that day.
Why It Matters
Organigram's upcoming earnings report could impact stock performance, providing insights into its financial health and market position in the cannabis industry, influencing investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) urges Canadian policymakers to prioritize the cannabis sector in economic strategies following the recent federal election victory of Prime Minister Mark Carney.
Why It Matters
Organigram's call for cannabis sector recognition signals potential regulatory support, which could enhance market growth and profitability, affecting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Organigram Global Inc. (NASDAQ: OGI) announced that its brands SHRED, Edison, and Trailblazer received awards at the CNB Leadership Conference and Cannabis NB Cup, highlighting its market leadership in Canada.
Why It Matters
Recognition of Organigram's brands enhances its market position, boosts consumer trust, and potentially drives sales growth, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Organigram Global Inc. (NASDAQ: OGI, TSX: OGI), Canada's leading cannabis company, has made the recording of its recent OG Investor Session available online for stakeholders.
Why It Matters
Organigram's investor session enhances transparency and engagement, signaling a commitment to shareholder interests and potentially boosting investor confidence in the company's performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About OGI Stock
What is Organigram Holdings Inc.'s (OGI) stock forecast for 2025?
Analyst forecasts for Organigram Holdings Inc. (OGI) are not currently available. The stock is trading at $1.18.
Is OGI stock a good investment in 2025?
According to current analyst ratings, OGI has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OGI stock?
Price predictions from Wall Street analysts for OGI are not currently available. The stock is trading at $1.18.
What is Organigram Holdings Inc.'s business model?
The company operates within the cannabis industry, focusing on both medical and adult-use markets. It generates revenue through the sale of a diverse range of cannabis products, including dried flower, pre-rolls, edibles, and vape oils, while leveraging advanced cultivation technologies to ensure product quality and consistency.
What is the highest forecasted price for OGI Organigram Holdings Inc.?
Price targets from Wall Street analysts for OGI are not currently available. The stock is trading at $1.18.
What is the lowest forecasted price for OGI Organigram Holdings Inc.?
Price targets from Wall Street analysts for OGI are not currently available. The stock is trading at $1.18.
What is the overall OGI consensus from analysts for Organigram Holdings Inc.?
The overall analyst consensus for OGI is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are OGI stock price projections?
Stock price projections, including those for Organigram Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:18 PM UTC